ArriVent Announces Pricing of Upsized Initial Public Offering
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to...
Day: January 26, 2024
Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock
SAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the...
Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its...
ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)
Clinical experience with investigational ARC-EX® Therapy showcased on the main stage and in clinical abstracts during the 2024 NANS Annual...
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today...
CooperCompanies Announces Release Date for First Quarter 2024
SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO) today announced it will report first quarter 2024...
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of...
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA...
Introducing cutting-edge features to transform the dental experience: PreVu Software unveils AI-powered enhancements for smile simulation software
FORT LAUDERDALE, FLA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- PreVu Software, a pioneer in dental technology solutions, proudly announces the...
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared...
Safe Supply Streaming Co. Highlights Amsterdam Mayor’s Recent Call for New Regulation of Narcotics
Toronto, Ontario--(Newsfile Corp. - January 26, 2024) - Safe Supply Streaming Co. Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe...
Tinley’s Provides Corporate Updates and Announces Appointment of New Director and the Closing of its Oversubscribed Non-Brokered Private Placement and Debt Settlement
Toronto, Ontario and Los Angeles, California--(Newsfile Corp. - January 26, 2024) - The Tinley Beverage Company Inc. (CSE: TNY) (OTCQB:...
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
KELOWNA, BC / ACCESSWIRE / January 26, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage...